Niraparib+Abiraterone 100mg+500mg / 200mg+1000mg Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: 100mg+500mg / 200mg+1000mg

Reference Brands: AKEEGA (USA/EU)

Category: Oncology Cancer Care

Niraparib/Abiraterone is an oral dual-action anticancer therapy used for BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Niraparib is a PARP inhibitor that blocks DNA repair in cancer cells, leading to cell death, while Abiraterone acetate inhibits androgen biosynthesis, reducing tumor growth driven by male hormones. The combination is taken once daily with prednisone and is designed to improve treatment efficacy by targeting cancer through two complementary mechanisms. It is available as film-coated tablets in varying strengths.

Product Description:

This fixed-dose combination pairs a PARP inhibitor with an androgen biosynthesis inhibitor, and the pairing is not simply additive. Androgen receptor signalling drives the expression of DNA repair genes in prostate cancer, so suppressing it degrades the tumour's repair capacity; adding PARP inhibition then exploits that weakness. In tumours already carrying a BRCA mutation the effect compounds, which is why the combination outperforms abiraterone alone in that group specifically.

It is indicated for BRCA-mutated metastatic castration-resistant prostate cancer, taken once daily with prednisone or prednisolone and with continuing androgen deprivation. The steroid is mandatory, not optional: abiraterone blocks cortisol synthesis and causes mineralocorticoid excess without it, producing hypertension, hypokalaemia and fluid retention. Anaemia, thrombocytopenia, fatigue, nausea, hepatotoxicity requiring liver monitoring, and hypertension are the main adverse effects.

Sourcing notes. Originator product, on patent, in two tablet strengths corresponding to dose levels rather than to different patients — dose reduction requires the lower one. Requires BRCA testing, germline or somatic, at the destination. Note that prednisone is a mandatory co-medication and should be included in any supply plan. Oral solid, room temperature.